Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03939286
Previous Study | Return to List | Next Study

Multimodal Imaging Study on Physical Activity in Patients With Alzheimer`s Disease (DEMENTIA-MOVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03939286
Recruitment Status : Recruiting
First Posted : May 6, 2019
Last Update Posted : May 7, 2019
Sponsor:
Information provided by (Responsible Party):
RWTH Aachen University

Brief Summary:

This study aims to gain a better understanding of metabolic early changes in neurodegenerative diseases, in order to enable new diagnostic and therapeutic approaches in the future. Further, it aims to identify specific movement-induced changes at the cerebral level, on cognition, on quality of life and physical fitness, and on serology parameters in neurodegenerative diseases.

In general, valid biomarkers are needed for early diagnosis and prediction of disease progression. It has been hypothesized that metabolic changes may precede structural changes and may be examined by intervention with exercise therapy. The non-invasive, in vivo characterization and diagnosis of such metabolic changes is therefore of paramount importance. In this line, this research project is focused on applying magnetic resonance imaging (MRI) based metabolic imaging techniques such as sodium MRI and phosphorus magnetic resonance spectroscopy (MRS) with standard structural and functional MRI methods, combined with exercise training, in order to detect biomarkers early in different stages of neurodegenerative diseases. Moreover, this project aims to examine the sensitivity of metabolic imaging with sodium and phosphorus sequences over classical MRI imaging with whole body fat sequences, in order to detect cerebral alterations.

At the end, the medical benefit of the planned project lies in the fact that the expected findings are groundbreaking for the understanding of the phenomenology and pathobiology of neurodegenerative diseases. This is the basis for the development of new methods for early diagnosis and individualized medicine with the optimization of future treatment options.


Condition or disease Intervention/treatment Phase
Alzheimer Disease Other: Clinical-neurological and neuropsychological tests Diagnostic Test: Blood sampling Other: Assessment of physical activity via fitness tracker/diary Other: MRI-examinations Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: In total, about 50 study participants will be examined in a prodromal or symptomatic early stage of Alzheimer's disease. These should be distributed equally randomized into two groups: a movement group (n = 25) with intensified training (equipment, coordination, balance) and a control group with continuation of physical activity as usual and participation in a psychoeducational program (n = 25).
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Multimodal Imaging Study on Physical Activity in Patients With Alzheimer`s Disease
Actual Study Start Date : April 8, 2019
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : October 2021


Arm Intervention/treatment
movement group
intensified training (equipment, coordination, balance)
Other: Clinical-neurological and neuropsychological tests
The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.

Diagnostic Test: Blood sampling
Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.

Other: Assessment of physical activity via fitness tracker/diary
All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.

Other: MRI-examinations
Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI

control group
continuation of physical activity as usual
Other: Clinical-neurological and neuropsychological tests
The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.

Diagnostic Test: Blood sampling
Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.

Other: Assessment of physical activity via fitness tracker/diary
All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.

Other: MRI-examinations
Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI




Primary Outcome Measures :
  1. Metabolic changes of the brain induced by intervention program [ Time Frame: T1 (baseline), T3 (6 months, after intervention), T4 (optional, 1 year after intervention) ]
    Sodium MR Imaging

  2. Metabolic changes of the brain induced by intervention program [ Time Frame: T1 (baseline), T3 (6 months, after intervention), T4 (optional, 1 year after intervention) ]
    Phosphor MR Imaging

  3. Structural changes of the brain induced by intervention program [ Time Frame: T1 (baseline), T3 (6 months, after intervention), T4 (optional, 1 year after intervention) ]
    Standard MR Imaging



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • prodromal or early symptomatic Alzheimer's disease according to the S3 guidelines of the German Society of Neurology in relation to the IWG-2 criteria for the definition of probable Alzheimer's disease
  • Age between 50 and 80 years
  • Mini Mental State Examination (MMSE)> 19 (screening at least 12 weeks before baseline visit)
  • Cognitive ability to understand the task as well as regular participation in exercise program, based on assessment of the treating neurologist and / or neuropsychologist
  • For antidementive or antidepressant medication, stable medication for at least 30 days
  • No visual or auditory limitation preventing participation in cognitive and functional testing
  • Interested in regular participation for 6 months, doing domestic exercises
  • Presence of a written informed consent

Exclusion criteria:

  • Heart attack or evidence of coronary heart disease (angina) in the last 2 years
  • Severe systemic disease, which is expected to worsen during exercise
  • Difficult to adjust diabetes mellitus II
  • Difficult to set art. Hypertension in the last 6 months
  • Severe psychiatric illness
  • Severe orthopedic disease
  • Alcohol and / or drug abuse in the last 2 years
  • Chronic pain and / or musculoskeletal disease, which prevent regular physical activity
  • Acute fracture or orthopedic injury last month
  • cancer in the last 5 years (except basal cell and spinal cell carcinoma) Contraindications for MRI examination below 3 Tesla (for example, implantation of ferromagnetic parts) For study participants, the following measures must be observed due to the direct effects of the magnetic field, in particular the force exerted on para- or ferromagnetic bodies: Study participants with incorporated metallic implants are not admitted. Pregnancy or lactation, traumatic brain injury, neurological or psychiatric disorders (other than the neurological disease to be studied for patients), relevant and severe other medical conditions, e.g. metabolic, endocrinological or cardiac disorders, mental retardation, magnetic metal implants (also intrauterine spiral).

Furthermore, the spatial conditions in the magnet do not allow to examine persons with certain back complaints or a strong overweight. As a rule, a body mass index (BMI, weight [kg] / size2 [cm2]) of > 30 is the exclusion criterion. With regard to the participation in the exercise in advance with unclear suitability is a consultation with the attending family doctor regarding possible contraindications, which are a regular participation in a sports program in the way.

Specifically, as exclusion criteria count:

Diseases:

  • epilepsy
  • severe cardiac pre-existing conditions
  • Musculoskeletal disorders that are contrary to regular exercise
  • advanced osteoporosis
  • Increased fall risk / imbalance
  • Advanced Heart Failure, Shortness of Breath, Severe Pulmonary Disease, which are contrary to regular physical activity
  • Diabetes mellitus prone to hypoglycaemia and hyperglycemia

Conditions:

  • pregnancy
  • Uncertain knowledge about possibly existing pregnancy

Contraceptives:

  • Any type of intrauterine device
  • Spiral made of copper Metal-containing implants or devices in / on the body (all non-metal implants / devices / patches will undergo a thorough examination based on the MRI Safety

Listing www.mrisafety.com):

  • Pacemaker / implanted pacemaker wires
  • Implanted defibrillator
  • Drug pump / infusion device
  • Stimulation device / electrodes

Non-MRI-compatible implants, for example, surgical screws, plates, nails, etc:

  • vascular / lumen filters, wire rings, wire spirals, stents, vascular clips
  • Artificial heart valve
  • Transdermal patches
  • epithesis (or partial epithesis)
  • shunts, catheters, wire sutures

Metal in / on the body:

  • Splinter / gunshot wounds
  • Metal shards in the eye, even if everything was supposedly removed
  • Piercing

Dental metals:

  • Any type of implant in the jawbone area / dental implant older than 20 years
  • No contraindications: Amalgam fillings, inlays, crowns, single crowned teeth as a denture base for a denture termed a telescopic denture, firmly screwed dentures

Additional:

  • cochlear implant
  • Ventilation Tubes
  • tattoos / permanent make-up (only after the most exact examination and special approval see separate explanation)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03939286


Contacts
Layout table for location contacts
Contact: Kathrin Reetz, Prof. Dr. +49(0)241-80 36516 kreetz@ukaachen.de
Contact: Alexa Häger, Dr. med. +49(0)241-80 37212 ahaeger@ukaachen.de

Locations
Layout table for location information
Germany
RWTH Aachen University Hospital Recruiting
Aachen, NRW, Germany, 52074
Contact: Kathrin Reetz    +4902418036516 ext +4902418036516    kreetz@ukaachen.de   
Contact: Alexa Häger    +4902418037212 ext +4902418037212    ahaeger@ukaachen.de   
Sponsors and Collaborators
RWTH Aachen University
Investigators
Layout table for investigator information
Study Director: Jörg B. Schulz, Prof. Dr. Clinic for neurology University Hospital Aachen

Publications:

Layout table for additonal information
Responsible Party: RWTH Aachen University
ClinicalTrials.gov Identifier: NCT03939286     History of Changes
Other Study ID Numbers: 19-064
First Posted: May 6, 2019    Key Record Dates
Last Update Posted: May 7, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders